IGF-1 DES 1mg

• This product is for pharmaceutical purpose and research.
• This product is to be used for hormonal disorder under the guidance of pediatrition and dermatologist.

Dosage: Adult: SC IGF 1 deficiency Initial: 4 mcg/kg/day. May increase dose gradually. Max: 10 mcg/kg/day. HIV-associated wasting or cachexia 5 mcg/kg/day at bedtime. Can be administered multiples times a day.

Administration: Intramuscular or subcutaneous injection.

Warning: Please stirred properly do not shake. Monitor thyroid function; benign intracranial hypertension. DM; may require dose reduction in insulin. Pregnancy. Discontinue treatment if there is evidence of tumour growth. Monitoring in patients with scoliosis is recommended due to risk of progression of scoliosis.

Storage: Store at room temperature away from heat and direct sunlight prior to mixing. Refrigerate between 2-8’C post Mixing.

Contraindications: Acute critical illness due to heart or abdominal surgery, multiple accidental trauma or respiratory failure; active neoplasms, proliferative or preproliferative diabetic retinopathy; lactation; patients with closed epiphyses. Intracranial lesions. Patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment.

About: IGF-1 DES is a truncated, natural version (splice variant) of insulin-like growth factor-1. Naturally found in the brain, breast milk, and uterine tissue, IGF-1 DES stimulates hypertrophy and hyperplasia of a number of different cell lines. Research has shown this version of the protein to be more potent than standard IGF-1, mostly as a result of its enhanced bioavailability. Currently, researchers are looking at ways to utilize IGF-1 DES in the treatment of inflammatory bowel disease (IBD), autism, and a variety of neurological conditions. Research shows that it helps to maintain the health of synaptic connections in the central nervous system and, like all IGF-1, promotes the repair of muscle and connective tissue.

What is IGF-1 DES ?

IGF-1 DES is a truncated version of IGF-1 in which the tripeptide Gly-Pro-Glu is absent from the N-terminus end of the protein. It is actually a naturally occurring variant of IGF-1 and has been found in the human brain, cow colostrum, and pig uterine tissue. IGF-1 DES is 10 times more potent than IGF-1 in stimulating hypertrophy and proliferation of cells because it is not affected by IGF-1 binding proteins and therefore is more bioavailable. There is interest in using the peptide to induce anabolism in catabolic conditions (e.g. chronic illness) and in the treatment of inflammatory bowel disease.

IGF-1 DES has also been of keen interest in the treatment of a number of neurological and neurodevelopmental conditions. Researchers investigating autism and autism spectrum disorders have found that IGF-1 and its analogues have potent effects on the synaptic health of neurons. In animal models of autism, IGF-1 DES and IGF-1 have relieved symptoms and improved a number of the behavioral aspects of the condition.